Journal of applied microbiology · 2025
Mechanistic study of 3-Methoxy-5-hydroxy-2-(3-methyl-2-butenyl) bibenzyl from pigeon pea against MRSA and biofilms: a highly promising natural inhibitor.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Guang-Ying, Xiong Xiu-Bi, Chen Jia-Yan, Liao Long-Feng, Chen Gong, Zhou Jing-Dan, Yuan Jie, Wu Jie-Wei
Аннотация
AIMS: The study aimed to investigate the anti-methicillin-resistant Staphylococcus aureus (MRSA) and anti-biofilm activity of 3-methoxy-5-hydroxy-2-(3-methyl-2-butenyl) bibenzyl (DELC) isolated from Cajanus cajan (L.) Millsp (pigeon pea) leaves, while evaluating its biocompatibility and exploring its potential as an antibiotic alternative.
METHODS AND RESULTS: DELC exhibited potent anti-MRSA activity, with a minimum inhibitory concentration (MIC) of 3.12 μg/mL and MBC of 6.25 μg/mL. At 2 × MIC, it achieved complete eradication of 106 CFU/mL MRSA within 120 min, demonstrating faster bactericidal action than vancomycin.
ANTIBIOFILM STUDIES: 2 × MIC DELC inhibited biofilm formation as effectively as 4 × MIC vancomycin. In mature biofilms, merely 1/2 × MIC DELC penetrated and eliminated a portion of embedded viable bacteria-a feat unattainable even with 8 × MIC vancomycin.
MECHANISTIC STUDIES: DELC induced oxidative stress, generating ROS that damaged the bacterial membrane, causing nucleic acid leakage. It also suppressed α-hemolysin secretion.
RNA-SEQ ANALYSIS REVEALED: At 1 × MIC, DELC blocked ATP synthesis and repair systems, leading to metabolic inhibition and virulence attenuation. At ≥2 × MIC, it directly lysed bacterial cells.
BIOCOMPATIBILITY: DELC showed no hemolysis or cytotoxicity, indicating excellent safety.
CONCLUSIONS: DELC demonstrates potent anti-MRSA activity characterized by rapid bactericidal effects, a concentration-dependent dual mechanism-metabolic inhibition at low concentrations progressing to direct cellular lysis at higher concentrations, and superior antibiofilm capacity. Its outstanding biocompatibility strongly supports its clinical translation potential.
METHODS AND RESULTS: DELC exhibited potent anti-MRSA activity, with a minimum inhibitory concentration (MIC) of 3.12 μg/mL and MBC of 6.25 μg/mL. At 2 × MIC, it achieved complete eradication of 106 CFU/mL MRSA within 120 min, demonstrating faster bactericidal action than vancomycin.
ANTIBIOFILM STUDIES: 2 × MIC DELC inhibited biofilm formation as effectively as 4 × MIC vancomycin. In mature biofilms, merely 1/2 × MIC DELC penetrated and eliminated a portion of embedded viable bacteria-a feat unattainable even with 8 × MIC vancomycin.
MECHANISTIC STUDIES: DELC induced oxidative stress, generating ROS that damaged the bacterial membrane, causing nucleic acid leakage. It also suppressed α-hemolysin secretion.
RNA-SEQ ANALYSIS REVEALED: At 1 × MIC, DELC blocked ATP synthesis and repair systems, leading to metabolic inhibition and virulence attenuation. At ≥2 × MIC, it directly lysed bacterial cells.
BIOCOMPATIBILITY: DELC showed no hemolysis or cytotoxicity, indicating excellent safety.
CONCLUSIONS: DELC demonstrates potent anti-MRSA activity characterized by rapid bactericidal effects, a concentration-dependent dual mechanism-metabolic inhibition at low concentrations progressing to direct cellular lysis at higher concentrations, and superior antibiofilm capacity. Its outstanding biocompatibility strongly supports its clinical translation potential.